Several research projects are developed by the Cuban biopharmaceutical industry, including those aimed at preventing and treating neurodegenerative diseases, cardiovascular diseases and cancer, according to officials from the sector.
Characterized by its closed cycle line, from invention and development to production and marketing, the entity works on 422 projects, 393 of them are product-oriented and 29 technological, all under the aegis of the Group of Biotechnological and Pharmaceutical Industries of Cuba (BioCubafarma).
In a meeting with the press, its director Eduardo Martinez explained that one of the entity’s megaprojects is the program of therapeutic molecules for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ataxia and multiple sclerosis.
NeuroEpo is the name of this product developed by the Molecular Immunology Center, one of the 34 companies affiliated to BioCubaFarma.
Another of its leading entities, the Center for Genetic Engineering and Biotechnology, develops a clinical trial with a cardioprotector that reduces the size of the infarcted area by 78.9 percent.
After five years of existence, BioCubaFarma has among its missions the production of high technology medicines, equipment and services.
Considered an industry with broad impact for the economy, referring to the export, the official explained that the products reach 34 nations from all latitudes, from the implementation of a business model that includes technology transfer agreements with countries like Brazil, South Africa, Iran China and Viet Nam.
BioCubaFarma is a business organization that produces high technology medicines, equipment and services aimed at the improvement of human health, the generation of exportable goods and services and the production of food with advanced technologies. With more than 21,600 workers as human capital, hundreds of specialists of high professional level integrated to the research-production and 62 production facilities.